ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Regeneron Bolsters Ophthalmic Portfoli
In VivoThe 2023 pharmaceutical sales ranking of the top 100 Asian biopharma firms reveals a mix of company-specific and wider performance factors linked to both individual corporate fortunes and the changing
ScripGoing global, including through licensing out deals, is the only approach for Chinese biotech companies to survive now and in the following decade. At least this was a key message from the China biote
ScripInnovent Biologics, Inc. , Transcenta Holding Ltd. and Shanghai Henlius Biotech Co. Ltd. are leading Chinese drug makers’ latest efforts to extend the high-stakes undertaking of global pivotal Pha